BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: An C, Park MS, Kim D, Kim YE, Chung WS, Rhee H, Kim MJ, Kim KW. Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. Eur Radiol 2013;23:924-30. [PMID: 23138382 DOI: 10.1007/s00330-012-2685-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 2015;25:2859-68. [DOI: 10.1007/s00330-015-3686-3] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 12.7] [Reference Citation Analysis]
2 Alhasan A, Cerny M, Olivié D, Billiard J, Bergeron C, Brown K, Bodson-clermont P, Castel H, Turcotte S, Perreault P, Tang A. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Abdom Radiol 2019;44:517-28. [DOI: 10.1007/s00261-018-1762-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
3 Lee M, Baek SE, Moon J, Roh YH, Lim JS, Park MS, Kim MJ, Kim H. Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis. Oncotarget 2016;7:38513-22. [PMID: 27229529 DOI: 10.18632/oncotarget.9567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Kambadakone AR, Fung A, Gupta RT, Hope TA, Fowler KJ, Lyshchik A, Ganesan K, Yaghmai V, Guimaraes AR, Sahani DV, Miller FH. LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol 2018;43:56-74. [DOI: 10.1007/s00261-017-1325-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
5 Park YS, Lee J, Kim JW, Park CM, Lee CH. Second shot arterial phase to overcome degraded hepatic arterial phase in liver MR imaging. Eur Radiol 2019;29:2821-9. [DOI: 10.1007/s00330-018-5897-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
6 Qian L, Zhou Q, Cao X, Shen W, Suo S, Ma S, Qu G, Gong X, Yan Y, Xu J, Jiang L. A cascade-network framework for integrated registration of liver DCE-MR images. Comput Med Imaging Graph 2021;89:101887. [PMID: 33711732 DOI: 10.1016/j.compmedimag.2021.101887] [Reference Citation Analysis]
7 Cho YK, Kim JW, Kim MY, Cho HJ. Non-hypervascular Hypointense Nodules on Hepatocyte Phase Gadoxetic Acid-Enhanced MR Images: Transformation of MR Hepatobiliary Hypointense Nodules into Hypervascular Hepatocellular Carcinomas. Gut Liver. 2018;12:79-85. [PMID: 28798287 DOI: 10.5009/gnl17046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wang F, Numata K, Chuma M, Miwa H, Moriya S, Ogushi K, Okada M, Otani M, Inayama Y, Maeda S. A study on the inconsistency of arterial phase hypervascularity detection between contrast-enhanced ultrasound using sonazoid and gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid magnetic resonance imaging of hepatocellular carcinoma lesions. J Med Ultrason (2001) 2021;48:215-24. [PMID: 33721130 DOI: 10.1007/s10396-021-01086-2] [Reference Citation Analysis]
9 Son J, Hwang SH, Park S, Han K, Chung YE, Choi J, Kim M, Park M. Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA. Investigative Radiology 2019;54:494-9. [DOI: 10.1097/rli.0000000000000562] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
10 Lee DH, Lee JM, Lee JY, Kim SH, Kim JH, Yoon JH, Kim YJ, Lee JH, Yu SJ, Han JK, Choi BI. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation. J Hepatol 2015;62:1122-30. [PMID: 25529623 DOI: 10.1016/j.jhep.2014.12.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
11 Kim YY, Choi JY, Sirlin CB, An C, Kim MJ. Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS). Eur Radiol 2019;29:1124-32. [PMID: 30116960 DOI: 10.1007/s00330-018-5641-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
12 Hong SB, Lee NK, Kim S, Seo HI, Kim HS, Kim DU, Kim TU, Ryu HS. Modified CAIPIRINHA-VIBE without view-sharing on gadoxetic acid-enhanced multi-arterial phase MR imaging for diagnosing hepatocellular carcinoma: comparison with the CAIPIRINHA-Dixon-TWIST-VIBE. Eur Radiol 2019;29:3574-83. [PMID: 30993435 DOI: 10.1007/s00330-019-06095-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Cruite I, Tang A, Mamidipalli A, Shah A, Santillan C, Sirlin CB. Liver Imaging Reporting and Data System: Review of Major Imaging Features. Seminars in Roentgenology 2016;51:292-300. [DOI: 10.1053/j.ro.2016.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
14 Chung JW, Yu J, Choi JM, Cho E, Kim JH, Chung J. Subtraction Images From Portal Venous Phase Gadoxetic Acid–Enhanced MRI for Observing Washout and Enhancing Capsule Features in LI-RADS Version 2018. American Journal of Roentgenology 2020;214:72-80. [DOI: 10.2214/ajr.18.20797] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-68. [PMID: 26280007 DOI: 10.1159/000343875] [Cited by in Crossref: 274] [Cited by in F6Publishing: 272] [Article Influence: 39.1] [Reference Citation Analysis]
16 Huh J, Kim SY, Yeh BM, Lee SS, Kim KW, Wu EH, Wang ZJ, Zhao LQ, Chang WC. Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver. Korean J Radiol. 2015;16:1207-1215. [PMID: 26576109 DOI: 10.3348/kjr.2015.16.6.1207] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
17 Kim DH, Choi SH, Byun JH, Kang JH, Lim YS, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. J Hepatol 2019;71:534-42. [PMID: 31108157 DOI: 10.1016/j.jhep.2019.05.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
18 Stocker D, Becker AS, Barth BK, Skawran S, Kaniewska M, Fischer MA, Donati O, Reiner CS. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018–based classification of liver lesions? Eur Radiol 2020;30:2922-33. [DOI: 10.1007/s00330-019-06596-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Wu X, Li J, Wang C, Zhang G, Zheng N, Wang X. Application of Different Imaging Methods in the Early Diagnosis of Primary Hepatic Carcinoma. Gastroenterol Res Pract 2016;2016:8763205. [PMID: 26819614 DOI: 10.1155/2016/8763205] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
20 Barr DC, Hussain HK. Magnetic Resonance Imaging in Cirrhosis: What’s New? Topics in Magnetic Resonance Imaging 2014;23:129-49. [DOI: 10.1097/rmr.0000000000000017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Engelbrecht MR, Katz SS, van Gulik TM, Laméris JS, van Delden OM. Imaging of Perihilar Cholangiocarcinoma. American Journal of Roentgenology 2015;204:782-91. [DOI: 10.2214/ajr.14.12830] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 5.1] [Reference Citation Analysis]
22 Korean Society of Abdominal Radiology. Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 2017;18:427-43. [PMID: 28458595 DOI: 10.3348/kjr.2017.18.3.427] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
23 Choi SH, Kim SY, Lee SS, Shim JH, Byun JH, Baek S, Lee M. Subtraction Images of Gadoxetic Acid–Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma. American Journal of Roentgenology 2017;209:584-91. [DOI: 10.2214/ajr.16.17211] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
24 Joo I, Lee JM, Lee DH, Jeon JH, Han JK. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 2019;29:1724-32. [PMID: 30255250 DOI: 10.1007/s00330-018-5727-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
25 Renzulli M, Biselli M, Brocchi S, Granito A, Vasuri F, Tovoli F, Sessagesimi E, Piscaglia F, D'Errico A, Bolondi L, Golfieri R. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 2018;67:1674-82. [PMID: 29437912 DOI: 10.1136/gutjnl-2017-315384] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 17.8] [Reference Citation Analysis]
26 Tang A, Bashir MR, Corwin MT, Cruite I, Dietrich CF, Do RKG, Ehman EC, Fowler KJ, Hussain HK, Jha RC, Karam AR, Mamidipalli A, Marks RM, Mitchell DG, Morgan TA, Ohliger MA, Shah A, Vu KN, Sirlin CB; LI-RADS Evidence Working Group. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology 2018;286:29-48. [PMID: 29166245 DOI: 10.1148/radiol.2017170554] [Cited by in Crossref: 131] [Cited by in F6Publishing: 128] [Article Influence: 26.2] [Reference Citation Analysis]
27 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
28 Cha DI, Jang KM, Kim SH, Kang TW, Song KD. Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging. Eur Radiol 2017;27:4394-405. [DOI: 10.1007/s00330-017-4804-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
29 Kim M, Kang TW, Cha DI, Jang KM, Kim YK, Kim SH, Sinn DH, Kim K. Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images. Korean J Radiol 2019;20:236-45. [PMID: 30672163 DOI: 10.3348/kjr.2018.0339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Renzulli M, Brocchi S, Pettinari I, Biselli M, Clemente A, Corcioni B, Cappabianca S, Gaudiano C, Golfieri R. New MRI series for kidney evaluation: Saving time and money. Br J Radiol 2019;92:20190260. [PMID: 31046410 DOI: 10.1259/bjr.20190260] [Reference Citation Analysis]
31 Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 2014;271:200-10. [PMID: 24475840 DOI: 10.1148/radiol.13131305] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 11.7] [Reference Citation Analysis]